oncology services 

 

We understand how challenging it is to develop novel anticancer therapies. Charles River can facilitate your selection of the most active agent and the most appropriate dose regimens in a variety of xenograft and genetically engineered mouse models of tumor.

Using various in vitro and in vivo tumor models, Charles River’s Oncology Services are available to help customers evaluate novel anticancer therapies. We offer human xenograft and murine syngeneic models bearing tumor cell lines that are either obtained from commercial sources or provided to us directly from the customers. Our research scientists will also work closely with you to develop detailed study protocols to meet your project goals.

In Vitro Compound Efficacy Testing

This service involves the evaluation of cell proliferation and cell death in response to test article administration in cultured human or murine tumor cell lines.

Tumor Injection Service

Most frequently, tumor cells are implanted via subcutaneous injection into the flank of nude mice. 

  • Human tumor xenograft models are generated by inoculating a human tumor cell line into an immunodeficient rodent.
  • Syngeneic tumor models are created by inoculating a mouse or rat tumor cell line into the corresponding immunocompetent mouse or rat strain.

 

Once the implanted tumors reach a predetermined volume, we can transport the animal models to our customers ready for study (inject and ship) or perform compound efficacy studies under contract. Our tumor injection services can assist you in more optimal resource allocation.

In Vivo Compound Efficacy Studies

In an appropriate animal model, one or more therapeutic compounds may be administered to assess efficacy against tumor induction, latency, proliferation, and metastasis. Subcutaneous models provide a consistent and reproducible tool for evaluating tumor cell growth, as well as permit easy access to the mass for tumor treatment and ultrasound evaluation. Metastatic tumor incidence can be monitored through radiography, high-resolution ultrasound imaging, and necropsy. Customers have the option to receive raw data and analyzed data at the completion of a study. Ancillary laboratory services such as necropsy, histopathology, and molecular phenotyping (i.e., mRNA and protein expression patterns) are also available to help maximize data capture.

 

Tissue Biomarkers

To further characterize tumor models, quantitative PCR-based expression testing and immunohistopathology can determine effects on key cellular processes, such as cell proliferation, cell death, and angiogenesis. Quantitative analysis of biomarker expression can help define mechanism of action for targeted therapeutics and assess their efficacy.

In addition, a line of complimentary services is available to support your oncology research including immunodeficient models, cell line testing by PCR, lead optimization toxicology, and pharmacokinetic services.

For more information please call:

1.877.CRIVER1
askcharlesriver@crl.com

view all

News & Events

view all
Dec 01 Charles River Releases 2009 Resear...
Jul 29 Charles River Supports the Nationa...
Jan 27-Jan 28 Hamamatsu, Japan 25th Annual Meeting of the Japanese Society of Toxic...
Jan 11-Jan 16 San Diego, CA CHI's 8th Annual PepTalk Conference & Exhibition